v3.22.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
$ in Thousands
3 Months Ended
Mar. 31, 2022
USD ($)
$ / shares
shares
Mar. 31, 2021
USD ($)
$ / shares
shares
Income Statement [Abstract]    
Revenues $ 25,862 $ 18,013
Cost of revenues 6,344 3,862
Gross profit 19,518 14,151
Operating expenses:    
Research and development 7,329 5,297
Sales and marketing 10,520 6,651
General and administrative 11,466 2,391
Total operating expenses 29,315 14,339
Operating loss (9,797) (188)
Finance expenses, net (2,311) 1,569
Loss before taxes (7,486) (1,757)
Taxes on income 37 (179)
Net loss (7,449) (1,936)
Accretion of preferred stock to redemption value 0 (23,728)
Net loss attributable to common stockholders, basic (7,449) (25,664)
Net loss attributable to common stockholders, diluted $ (7,449) $ (25,664)
Net loss per stock attributable to common stockholders    
Basic (in dollars per share) | $ / shares [1] $ (0.06) $ (1.55)
Diluted Basic (in dollars per share) | $ / shares [1] $ (0.06) $ (1.55)
Weighted-average number of stocks used in computing net loss per stock attributable to common stockholders    
Basic (in shares) | shares [1] 124,245,358 16,547,808
Diluted (in shares) | shares [1] 124,245,358 16,547,808
[1] Prior period results have been adjusted to reflect the exchange of Innovid Inc’s common stock for Innovid Corp’s common stock at an exchange ratio of approximately 1.337 as a result of the Transaction. See Note 3, “Transaction and Business Combination” in the notes to the unaudited interim condensed consolidated financial statements for further details.

Source